Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Alan Lau"'
Autor:
Philip J. Jewsbury, Rajesh Odedra, Alan Lau, Sylvie Guichard, James W.T. Yates, Kevin Blades, Gary Wilkinson, Kevin Michael Foote, Dan Heathcote, Turner Paul, Christine M. Wood, J. Willem M. Nissink, Zena Wilson, Thomas M. McGuire
Publikováno v:
Journal of Medicinal Chemistry. 61:9889-9907
The kinase ataxia telangiectasia mutated and rad3 related (ATR) is a key regulator of the DNA-damage response and the apical kinase which orchestrates the cellular processes that repair stalled replication forks (replication stress) and associated DN
Autor:
James W.T. Yates, Yann Wallez, Charles R. Dunlop, Frances M. Richards, Chiara Fornari, Siang-Boon Koh, Timothy Isaac Johnson, Duncan I. Jodrell, Alan Lau, Sandra Bernaldo de Quirós Fernández
Publikováno v:
Molecular Cancer Therapeutics. 17:1670-1682
Pancreatic ductal adenocarcinoma (PDAC) is among the deadliest cancers, and overall survival rates have barely improved over the past five decades. The antimetabolite gemcitabine remains part of the standard of care but shows very limited antitumor e
Autor:
Elkhan Sanay, Emma Dean, Natalia Lukashchuk, Andrew J. Pierce, Nisha Kurian, Graeme Parr, Bienvenu Loembe, Alan Lau, Wessel de Graaf, Rahul Aggarwal, Wassim Abida, Vidalba Rocher Ros
Publikováno v:
Journal of Clinical Oncology. 39:TPS189-TPS189
TPS189 Background: Ataxia telangiectasia mutated (ATM) and ataxia telangiectasia and Rad3-related (ATR) are kinases that orchestrate cellular responses to DNA damage. ATM is primarily activated by DNA double strand breaks, and ATR is recruited to reg
Autor:
Sébastien L. Degorce, Steven C. Glossop, Alan Lau, Elaine Cadogan, Barlaam Bernard Christophe, Richard Ducray, Kurt Gordon Pike, Andrew G. Thomason, Gilles Ouvry, Allan Dishington, Franck Lach, Lorraine A. Hassall, Thomas M. McGuire, Thorsten Nowak
Publikováno v:
Journal of Medicinal Chemistry. 59:6281-6292
A novel series of 3-quinoline carboxamides has been discovered and optimized as selective inhibitors of the ataxia telangiectasia mutated (ATM) kinase. From a modestly potent HTS hit (4), we identified molecules such as 6-[6-(methoxymethyl)-3-pyridin
Autor:
Mark J. O'Connor, Sandra Schamus, Thomas P. Conrads, Frank P. Vendetti, Christopher J. Bakkenist, Alan Lau
Publikováno v:
Oncotarget
ATR and ATM are DNA damage signaling kinases that phosphorylate several thousand substrates. ATR kinase activity is increased at damaged replication forks and resected DNA double-strand breaks (DSBs). ATM kinase activity is increased at DSBs. ATM has
Autor:
Alan Lau, Charles R. Dunlop, Saadia A. Karim, Duncan I. Jodrell, Yann Wallez, Frances M. Richards, Sandra Bernaldo de Quirós Fernández
Publikováno v:
Cancer Research. 79:271-271
Therapeutic targeting of the DNA damage response (DDR) has the potential to improve the poor survival outcomes of pancreatic ductal adenocarcinoma (PDAC). Many common genetic alterations in PDAC augment replication stress, which activates Ataxia-tela
Autor:
Jiri Bartek, Zena Wilson, Lucy H. Young, Mark J. O'Connor, Corinne Reimer, Alan Lau, Lenka Oplustil O'Connor
Publikováno v:
Cancer Research. 78:2826-2826
The checkpoint kinases ATR and WEE1 protect cells from replication stress (RS), a hallmark of cancer that has potential to be exploited for cancer treatment. ATR and WEE1 inhibitors are in early clinical trials. Here we report selective anti-tumour a
Autor:
Simon J. Hollingsworth, Andrew Bloecher, Alan Lau, Oona Delpuech, Kate Wills, Brandon Willis, Lucy H. Young, Todd Covey, Michelle DuPont, Alexandra Bussey, Zena Wilson, Carlos Grajales
Publikováno v:
Cancer Research. 78:LB-263
Bruton tyrosine kinase (BTK) is an essential kinase in the B-cell receptor (BCR) signalling pathway. Acalabrutinib is a potent and highly selective irreversible BTK inhibitor that received accelerated approval by FDA for the treatment of Relapsed/Ref
Autor:
Philip J. Jewsbury, Steve Powell, Rajesh Odedra, Clifford David Jones, Sylvie Guichard, Dan Heathcote, Kevin Michael Foote, Jen Barnes, Martin Pass, Alan Lau, Elaine Brown, A. Hughes, J. Willem M. Nissink
Publikováno v:
Cancer Research. 73:3343-3343
AZD6738 is a potent and selective orally bioavailable kinase inhibitor of ataxia telangiectasia and rad3 related (ATR). Here we report the pre-clinical in vitro and in vivo and biological profile of AZD6738. ATR is a serine/threonine protein kinase i
Autor:
Nicola J. Curtin, Louise J. Jones, Yan Zhao, Julia Bardos, Kerry Shea, Mark J. O'Connor, Graeme C. M. Smith, Aaron Cranston, Roger J. Griffin, Niall M. B. Martin, Pia Thommes, Alan Lau, Michael A. Batey, Mark Albertella, Caroline Richardson, David R. Newell, Keith Allan Menear
Publikováno v:
Cancer Research. 70:3928-3928
Ataxia telangiectasia mutated (ATM) is an important serine/threonine kinase involved in the DNA damage response and cell cycle checkpoint control. The 350kDa protein is a member of the PI3-kinase like kinase (PIKK) family and is mutated in the neurod